You won't need much money to start investing in these great stocks.A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now. Here's why they picked AstraZeneca (AZN 0.41%), Bristol Myers Squibb (BMY 2.17%), and Pfizer (PFE).AstraZeneca is a growth beast with loads of potential upsideDavid Jagielski (AstraZeneca): Shares of AstraZ ...

AstraZeneca (AZN) announced that the European Commission (EC) has approved Truqap (capivasertib) in combination with Faslodex (fulvestrant) for a breast cancer indication.The EC has approved Truqap in combination with Faslodex for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have qualifying alterations in the PIK3CA, AKT1 or PTEN genes following recurrence or progression on or after an endocrine-based regimen.Following ...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute's (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: "… the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to t ...

AstraZeneca (AZN) announced that a phase III study evaluating its newly approved breast cancer drug, Truqap (capivasertib), for treating advanced or metastatic triple-negative breast cancer (TNBC), has failed to meet its dual primary endpoints.The CAPItello-290 study investigated the safety and efficacy of Truqap in combination with paclitaxel (chemotherapy) versus placebo in combination with paclitaxel for the first-line treatment of patients with locally advanced (inoperable) or metastatic TNBC.In the stu ...

Astrazeneca (AZN) closed at $79.31 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily gain of 0.77%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.95%.The pharmaceutical's shares have seen an increase of 3.5% over the last month, surpassing the Medical sector's gain of 1.49% and falling behind the S&P 500's gain of 3.71%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upco ...

AstraZeneca (AZN) announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) plus chemotherapy, followed by Imfinzi monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.The approval for expanded use of Imfinzi was based on data from a prespecified exploratory subgroup analysis by MMR status in the phase III DUO-E study.Data from the study showed that treatment with Imfinzi in combination with carboplatin and ...

AstraZeneca (AZN) announced that the FDA has accepted its supplemental new drug application (sNDA), seeking expanded use of its blockbuster lung cancer drug, Tagrisso (osimertinib) in EGFR-mutated lung cancer.The sNDA is seeking approval for Tagrisso for the treatment of adult patients with unresectable, stage III EGFR-mutated non-small cell lung cancer (NSCLC) following treatment with chemoradiotherapy (CRT).With the FDA granting a priority review to the sNDA, a decision from the regulatory body is expecte ...

Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism. So far in 2024, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY), which tracks the S&P 500 index, is up 13%. Similarly, the Invesco QQQ Trust ETF (NYSEARCA:QQQ), which tracks the Nasdaq-100, rose 14% since January, while the SPDR Dow Jones Industrial Average ETF Trust ...

AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drug maker believes it can almost double revenues by 2030."Biology is complicated, and we're never sure of anything. But we have a great level of confidence we can get there, and I think this target forces us to think creatively and be ambitious and stretch," Soriot said. "But we have a large portfolio of existing products, several blockbusters...growing strongly, and we have another 20 medicines to launch, so we s ...

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its ...